BioInvent International AB (publ) (STO:BINV)

Market Cap	1.73B -7.4%
Revenue (ttm)	244.85M +533.7%
Net Income	-323.94M
EPS	-4.93
Shares Out	65.80M
PE Ratio	n/a
Forward PE	2.70
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,643
Average Volume	103,842
Open	26.35
Previous Close	26.30
Day's Range	25.90 - 27.05
52-Week Range	22.70 - 41.60
Beta	-0.03
RSI	33.76
Earnings Date	Feb 26, 2026

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 124
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2024, STO:BINV's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.